both decrease cholinergic effects/transmission. Use Caution/Monitor.benperidolMonitor Closely (3)flavoxate decreases levels of benperidol by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor. flavoxate decreases levels of benperidol by pharmacodynamic antagonism. Use Caution/Monitor. benperidol increases effects of flavoxate by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia.benztropineMonitor Closely (1)benztropine and flavoxate both decrease cholinergic effects/transmission. Use Caution/Monitor. Additive anticholinergic adverse effects may be seen with concurrent use. bethanecholMonitor Closely (1)bethanechol increases and flavoxate decreases cholinergic effects/transmission. Effect of interaction is not clear, use caution. Use Caution/Monitor.carbacholMonitor Closely (1)carbachol increases and flavoxate decreases cholinergic effects/transmission. Effect of interaction is not clear, use caution. Use Caution/Monitor.cevimelineMonitor Closely (1)cevimeline increases and flavoxate decreases cholinergic effects/transmission. Effect of interaction is not clear, use caution. Use Caution/Monitor.chlorpromazineMonitor Closely (3)flavoxate decreases levels of chlorpromazine by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor. flavoxate decreases levels of chlorpromazine by pharmacodynamic antagonism. Use Caution/Monitor. chlorpromazine increases effects of flavoxate by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia.cisatracuriumMonitor Closely (1)cisatracurium and flavoxate both decrease cholinergic effects/transmission. Use Caution/Monitor.clomipramineMonitor Closely (1)flavoxate and clomipramine both decrease cholinergic effects/transmission. Use Caution/Monitor.clozapineMonitor Closely (3)flavoxate decreases levels of clozapine by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor. flavoxate decreases levels of clozapine by pharmacodynamic antagonism. Use Caution/Monitor. clozapine increases effects of flavoxate by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia.cyclizineMonitor Closely (1)cyclizine and flavoxate both decrease cholinergic effects/transmission. Use Caution/Monitor.cyclobenzaprineMonitor Closely (1)cyclobenzaprine and flavoxate both decrease cholinergic effects/transmission. Use Caution/Monitor.darifenacinMonitor Closely (1)darifenacin and flavoxate both decrease cholinergic effects/transmission. Use Caution/Monitor.desipramineMinor (1)flavoxate and desipramine both decrease cholinergic effects/transmission. Minor/Significance Unknown.dicyclomineMonitor Closely (1)dicyclomine and flavoxate both decrease cholinergic effects/transmission. Use Caution/Monitor.digoxinMinor (1)flavoxate increases effects of digoxin by unspecified interaction mechanism. Minor/Significance Unknown.dimenhydrinateMinor (1)dimenhydrinate increases toxicity of flavoxate by pharmacodynamic synergism. Minor/Significance Unknown. Additive anticholinergic effects.diphenhydramineMonitor Closely (1)diphenhydramine and flavoxate both decrease cholinergic effects/transmission. Use Caution/Monitor.donepezilMonitor Closely (1)donepezil increases and flavoxate decreases cholinergic effects/transmission. Effect of interaction is not clear, use caution. Use Caution/Monitor.Minor (1)donepezil decreases effects of flavoxate by pharmacodynamic antagonism. Minor/Significance Unknown.donepezil transdermalMonitor Closely (1)donepezil transdermal, flavoxate. Either decreases effects of the other by pharmacodynamic antagonism. Use Caution/Monitor.dosulepinMonitor Closely (1)flavoxate and dosulepin both decrease cholinergic effects/transmission. Use Caution/Monitor.doxepinMonitor Closely (1)flavoxate and doxepin both decrease cholinergic effects/transmission. Use Caution/Monitor.droperidolMonitor Closely (3)flavoxate decreases levels of droperidol by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor. flavoxate decreases levels of droperidol by pharmacodynamic antagonism. Use Caution/Monitor. droperidol increases effects of flavoxate by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia.echothiophate iodideMonitor Closely (1)echothiophate iodide increases and flavoxate decreases cholinergic effects/transmission. Effect of interaction is not clear, use caution. Use Caution/Monitor.fesoterodineMonitor Closely (1)fesoterodine and flavoxate both decrease cholinergic effects/transmission. Use Caution/Monitor.fluphenazineMonitor Closely (3)flavoxate decreases levels of fluphenazine by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor. flavoxate decreases levels of fluphenazine by pharmacodynamic antagonism. Use Caution/Monitor. fluphenazine increases effects of flavoxate by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia.galantamineMonitor Closely (1)galantamine increases and flavoxate decreases cholinergic effects/transmission. Effect of interaction is not clear, use caution. Use Caution/Monitor.Minor (1)galantamine decreases effects of flavoxate by pharmacodynamic antagonism. Minor/Significance Unknown.glycopyrrolateMonitor Closely (1)flavoxate and glycopyrrolate both decrease cholinergic effects/transmission. Use Caution/Monitor.glycopyrrolate inhaledMonitor Closely (1)flavoxate and glycopyrrolate inhaled both decrease cholinergic effects/transmission. Use Caution/Monitor.haloperidolMonitor Closely (3)flavoxate decreases levels of haloperidol by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor. flavoxate decreases levels of haloperidol by pharmacodynamic antagonism. Use Caution/Monitor. haloperidol increases effects of flavoxate by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia.henbaneMonitor Closely (1)flavoxate and henbane both decrease cholinergic effects/transmission. Use Caution/Monitor.homatropineMonitor Closely (1)flavoxate and homatropine both decrease cholinergic effects/transmission. Use Caution/Monitor.huperzine AMonitor Closely (1)huperzine A increases and flavoxate decreases cholinergic effects/transmission. Effect of interaction is not clear, use caution. Use Caution/Monitor.hyoscyamineMonitor Closely (1)flavoxate and hyoscyamine both decrease cholinergic effects/transmission. Use Caution/Monitor.hyoscyamine sprayMonitor Closely (1)flavoxate and hyoscyamine spray both decrease cholinergic effects/transmission. Use Caution/Monitor.iloperidoneMonitor Closely (3)flavoxate decreases levels of iloperidone by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor. flavoxate decreases levels of iloperidone by pharmacodynamic antagonism. Use Caution/Monitor. iloperidone increases effects of flavoxate by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia.imipramineMonitor Closely (1)flavoxate and imipramine both decrease cholinergic effects/transmission. Use Caution/Monitor.ipratropiumMonitor Closely (1)flavoxate and ipratropium both decrease cholinergic effects/transmission. Use Caution/Monitor. Due to the poor systemic absorption of ipratropium, interaction unlikely at regularly recommended dosages.levodopaMinor (1)flavoxate, levodopa. Other (see comment). Minor/Significance Unknown. Comment: Anticholinergic agents may enhance the therapeutic effects of levodopa; however, anticholinergic agents can exacerbate tardive dyskinesia. In high dosage, anticholinergics may decrease the effects of levodopa by delaying its GI absorption. .lofepramineMonitor Closely (1)flavoxate and lofepramine both decrease cholinergic effects/transmission. Use Caution/Monitor.loxapineMonitor Closely (3)flavoxate decreases levels of loxapine by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor. flavoxate decreases levels of loxapine by pharmacodynamic antagonism. Use Caution/Monitor. loxapine increases effects of flavoxate by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia.loxapine inhaledMonitor Closely (2)loxapine inhaled increases effects of flavoxate by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia. flavoxate decreases levels of loxapine inhaled by pharmacodynamic antagonism. Use Caution/Monitor.maprotilineMonitor Closely (1)flavoxate and maprotiline both decrease cholinergic effects/transmission. Use Caution/Monitor.meclizineMonitor Closely (1)flavoxate and meclizine both decrease cholinergic effects/transmission. Use Caution/Monitor.methscopolamineMonitor Closely (1)flavoxate and methscopolamine both decrease cholinergic effects/transmission. Use Caution/Monitor.neostigmineMonitor Closely (1)neostigmine increases and flavoxate decreases cholinergic effects/transmission. Effect of interaction is not clear, use caution. Use Caution/Monitor.nortriptylineMonitor Closely (1)flavoxate and nortriptyline both decrease cholinergic effects/transmission. Use Caution/Monitor.olanzapineMonitor Closely (3)flavoxate decreases levels of olanzapine by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor. flavoxate decreases levels of olanzapine by pharmacodynamic antagonism. Use Caution/Monitor. olanzapine increases effects of flavoxate by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia.onabotulinumtoxinAMonitor Closely (1)onabotulinumtoxinA and flavoxate both decrease cholinergic effects/transmission. Use Caution/Monitor.orphenadrineMonitor Closely (1)flavoxate and orphenadrine both decrease cholinergic effects/transmission. Use Caution/Monitor.oxybutyninMonitor Closely (1)flavoxate and oxybutynin both decrease cholinergic effects/transmission. Use Caution/Monitor.oxybutynin topicalMonitor Closely (1)flavoxate and oxybutynin topical both decrease cholinergic effects/transmission. Use Caution/Monitor.oxybutynin transdermalMonitor Closely (1)flavoxate and oxybutynin transdermal both decrease cholinergic effects/transmission. Use Caution/Monitor.paliperidoneMonitor Closely (3)flavoxate decreases levels of paliperidone by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor. flavoxate decreases levels of paliperidone by pharmacodynamic antagonism. Use Caution/Monitor. paliperidone increases effects of flavoxate by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia.pancuroniumMonitor Closely (1)flavoxate and pancuronium both decrease cholinergic effects/transmission. Use Caution/Monitor.perphenazineMonitor Closely (3)flavoxate decreases levels of perphenazine by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor. flavoxate decreases levels of perphenazine by pharmacodynamic antagonism. Use Caution/Monitor. perphenazine increases effects of flavoxate by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia.physostigmineMonitor Closely (1)physostigmine increases and flavoxate decreases cholinergic effects/transmission. Effect of interaction is not clear, use caution. Use Caution/Monitor.pilocarpineMonitor Closely (1)pilocarpine increases and flavoxate decreases cholinergic effects/transmission. Effect of interaction is not clear, use caution. Use Caution/Monitor.pimozideMonitor Closely (3)flavoxate decreases levels of pimozide by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor. flavoxate decreases levels of pimozide by pharmacodynamic antagonism. Use Caution/Monitor. pimozide increases effects of flavoxate by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia.pralidoximeMonitor Closely (1)flavoxate and pralidoxime both decrease cholinergic effects/transmission. Use Caution/Monitor.pramlintideSerious - Use Alternative (1)pramlintide, flavoxate. Either increases effects of the other by pharmacodynamic synergism. Contraindicated. Synergistic inhibition of GI motility.prochlorperazineMonitor Closely (3)flavoxate decreases levels of prochlorperazine by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor. flavoxate decreases levels of prochlorperazine by pharmacodynamic antagonism. Use Caution/Monitor. prochlorperazine increases effects of flavoxate by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia.promethazineMonitor Closely (3)flavoxate decreases levels of promethazine by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor. flavoxate decreases levels of promethazine by pharmacodynamic antagonism. Use Caution/Monitor. promethazine increases effects of flavoxate by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia.propanthelineMonitor Closely (1)flavoxate and propantheline both decrease cholinergic effects/transmission. Use Caution/Monitor.protriptylineMonitor Closely (1)flavoxate and protriptyline both decrease cholinergic effects/transmission. Use Caution/Monitor.pyridostigmineMonitor Closely (1)pyridostigmine increases and flavoxate decreases cholinergic effects/transmission. Effect of interaction is not clear, use caution. Use Caution/Monitor.quetiapineMonitor Closely (3)flavoxate decreases levels of quetiapine by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor. flavoxate decreases levels of quetiapine by pharmacodynamic antagonism. Use Caution/Monitor. quetiapine increases effects of flavoxate by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia.rapacuroniumMonitor Closely (1)flavoxate and rapacuronium both decrease cholinergic effects/transmission. Use Caution/Monitor.risperidoneMonitor Closely (3)flavoxate decreases levels of risperidone by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor. flavoxate decreases levels of risperidone by pharmacodynamic antagonism. Use Caution/Monitor. risperidone increases effects of flavoxate by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia.rocuroniumMonitor Closely (1)flavoxate and rocuronium both decrease cholinergic effects/transmission. Use Caution/Monitor.scopolamineMonitor Closely (1)flavoxate and scopolamine both decrease cholinergic effects/transmission. Use Caution/Monitor.secretinSerious - Use Alternative (1)flavoxate decreases effects of secretin by pharmacodynamic antagonism. Avoid or Use Alternate Drug. Concomitant use of anticholinergic drugs may cause a hyporesponse to stimulation testing with secretin. Discontinue anticholinergic drugs at least 5 half-lives before administering secretin.solifenacinMonitor Closely (1)flavoxate and solifenacin both decrease cholinergic effects/transmission. Use Caution/Monitor.succinylcholineMonitor Closely (1)succinylcholine increases and flavoxate decreases cholinergic effects/transmission. Effect of interaction is not clear, use caution. Use Caution/Monitor.thioridazineMonitor Closely (3)flavoxate decreases levels of thioridazine by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor. flavoxate decreases levels of thioridazine by pharmacodynamic antagonism. Use Caution/Monitor. thioridazine increases effects of flavoxate by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia.thiothixeneMonitor Closely (3)flavoxate decreases levels of thiothixene by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor. flavoxate decreases levels of thiothixene by pharmacodynamic antagonism. Use Caution/Monitor. thiothixene increases effects of flavoxate by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia.tiotropiumMonitor Closely (1)flavoxate and tiotropium both decrease cholinergic effects/transmission. Use Caution/Monitor.tolterodineMonitor Closely (1)flavoxate and tolterodine both decrease cholinergic effects/transmission. Use Caution/Monitor.trazodoneMinor (1)flavoxate and trazodone both decrease cholinergic effects/transmission. Minor/Significance Unknown.trifluoperazineMonitor Closely (3)flavoxate decreases levels of trifluoperazine by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor. flavoxate decreases levels of trifluoperazine by pharmacodynamic antagonism. Use Caution/Monitor. trifluoperazine increases effects of flavoxate by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia.trihexyphenidylMonitor Closely (1)flavoxate and trihexyphenidyl both decrease cholinergic effects/transmission. Use Caution/Monitor. Potential for additive anticholinergic effects.trimipramineMonitor Closely (1)flavoxate and trimipramine both decrease cholinergic effects/transmission. Use Caution/Monitor.trospium chlorideMonitor Closely (1)flavoxate and trospium chloride both decrease cholinergic effects/transmission. Use Caution/Monitor.vecuroniumMonitor Closely (1)flavoxate and vecuronium both decrease cholinergic effects/transmission. Use Caution/Monitor.ziprasidoneMonitor Closely (3)flavoxate decreases levels of ziprasidone by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor. flavoxate decreases levels of ziprasidone by pharmacodynamic antagonism. Use Caution/Monitor. ziprasidone increases effects of flavoxate by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia.zotepineMonitor Closely (2)flavoxate decreases levels of zotepine by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor. flavoxate decreases levels of zotepine by pharmacodynamic antagonism. Use Caution/Monitor. Frequency Not Defined Abdominal pain Blurred vision Confusion Constipation Disturbance in ocular accommodation Drowsiness Dry mouth/throat Dysuria Eosinophilia Headache Hyperpyrexia Increased ocular tension Nausea Nervousness Palpitation Tachycardia Urticaria Vertigo Vomiting Contraindications Obstructive uropathy of lower urinary tract, pyloric/duodenal obstruction, ileus, GI bleeding, achalasia Cautions Use with caution in patients with glaucoma May cause ocular disturbances; advise patients of potential effects Vertigo may occur Inform patients that if drowsiness and blurred vision occur, not to operate a motor vehicle or machinery or participate in activities where alertness is required Pregnancy There are no well-controlled studies on pregnant women Animal data Reproduction studies performed in rats and rabbits at doses up to 34 times human dose revealed no evidence of impaired fertility or harm to fetus due to this drug Because animal reproduction studies are not always predictive of human response, this drug should be used during pregnancy only if clearly needed Lactation Not known whether this drug is excreted in human milk; because many drugs are excreted in human milk, exercise caution when administered to a nursing womanPregnancy Categories A: Generally acceptable. Controlled studies in pregnant women show no evidence of fetal risk. B: May